Showing results (131-140 of 155) with videos related to

Sort By:
Pageof 16
International Journal of Hematology|March 5, 2011
Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasiroxVip Viprakasit, Hishamshah Ibrahim, Shau-Yin Ha, et al.
Annals of Hematology|May 25, 2023
Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemiaVip Viprakasit, Mona M Hamdy, Hoda M A Hassab, et al.
Human Genetics|February 26, 2010
A genome-wide association identified the common genetic variants influence disease severity in beta0-thalassemia/hemoglobin EManit Nuinoon, Wattanan Makarasara, Taisei Mushiroda, et al.
Human Molecular Genetics|August 14, 2003
Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosisAlison T Merryweather-Clarke, Estelle Cadet, Adrian Bomford, et al.
Science (New York, N.Y.)|May 27, 2006
A regulatory SNP causes a human genetic disease by creating a new transcriptional promoterMarco De Gobbi, Vip Viprakasit, Jim R Hughes, et al.
Blood|January 21, 2014
Mutations in Kruppel-like factor 1 cause transfusion-dependent hemolytic anemia and persistence of embryonic globin gene expressionVip Viprakasit, Supachai Ekwattanakit, Suchada Riolueang, et al.
Haematologica|January 25, 2012
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia majorDudley J Pennell, John B Porter, Maria Domenica Cappellini, et al.
Haematologica|November 13, 2010
Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overloadDudley J Pennell, John B Porter, Maria Domenica Cappellini, et al.
BMJ Open|March 23, 2023
The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study designRachael F Grace, Eduard J van Beers, Joan-Lluis Vives Corrons, et al.
Blood|December 10, 2009
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemiaDudley J Pennell, John B Porter, Maria Domenica Cappellini, et al.
Pageof 16